Evelyn Beas-Lozano, MD

Articles by Evelyn Beas-Lozano, MD

Evaluating HRR and MMR in Advanced Prostate Cancer: © Sebastian Kaulitzki - stock.adobe.com

Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City

ByJosé Luis Rodríguez-Olivares, MD,Mauricio Mora Pineda, MD,Evelyn Beas-Lozano, MD,Alec Seidman-Sorsby, MD,Yuly A. Remolina-Bonilla, MD, MSc,Armando Gamboa-Domínguez, MD,Jeffrey Weitzel, MD, FACMG,Pedro Barata, MD, MSc,Yanin Chavarri-Guerra, MD, MSc, FASCO,María T. Bourlon, MD, MSc, FASCO

July 22nd 2026

This cross-sectional study evaluated the genetic landscape of a cohort of patients with metastatic prostate cancer who were treated at a referral center in Mexico City, Mexico.

Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma

ByFrancisco J. Castro-Alonso, MD,Evelyn Beas-Lozano, MD,Yuly A. Remolina-Bonilla, MD, MSc,Thomas W. Flaig, MD,María T. Bourlon, MD, MSc, FASCO

June 23rd 2023

Francisco Castro-Alonso, MD, and colleagues describe the effects of the use of erdafitinib in a patient with metastatic urothelial bladder cancer.

Evelyn Beas-Lozano, MD

Articles by Evelyn Beas-Lozano, MD

Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City

Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma

Latest Updated Articles

Trending on CancerNetwork

Lenvatinib/Pembrolizumab Shows Promise After IO Progression in GYN Cancers

Belzutifan Combo Improves Disease Control Vs Cabozantinib in Advanced RCC

FDA Issues Another CRL for Amorphous Dasatinib Receives in CML and ALL

Lymphoma's Revolution: Evens & Rhodes on CLL, CAR-T, and NJ Care

How Have Bispecific Antibodies Evolved in Multiple Myeloma?